U.S. markets closed

Wilmington Trust Retirement and Institutional Services Company - Target Date 2025 Fund (WBRLRX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
Add to watchlist
28.680.00 (0.00%)
At close: 6:46PM EDT
Full screen
Previous Close28.68
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Cathie Wood’s Top 10 Stock Picks
    Insider Monkey

    Cathie Wood’s Top 10 Stock Picks

    In this article we discuss Cathie Wood’s top 10 stock picks. You can skip our detailed analysis of Cathie Wood’s investment strategy and go directly to Cathie Wood’s Top 5 Stock Picks. Ark Investment’s Cathie Wood has become one of the most popular hedge fund managers and investors, thanks to her successful bets on technology, […]

  • Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference
    PR Newswire

    Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:40 a.m. Eastern / 7:40 a.m. Pacific.

  • PR Newswire

    Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, in collaboration with Invitae Corporation (NYSE: NVTA, "Invitae"), a leading medical genetics company, announces the launch of a sponsored genetic testing program, navigateAPDS, designed to assist clinicians in identifying patients and their family members with activated PI3K delta syndrome (APDS), which may lead to earlier diagnosis.